- Cronos Group to Begin Trading on Nasdaq Stock Exchange
- The Globe and Mail
- Editors' Picks
- SITE TOUR: Cronos Group Inc (NASDAQ:CRON) Cannabis Production Backstage Pass
- Related Articles
- Your data, your experience
- Cronos Group: This Weed Stock Has Double-Digit Upside
- Crons group ipo info
- Cronos Group Issues Statement on Separately Announced IPO of Cronos Australia
Cronos Group is an innovative global cannabinoid company
With international production and distribution across five continents Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development.
With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group’s portfolio includes PEACE NATURALS™, a global health and wellness platform, two adult-use brands, COVE™ and Spinach™, and two hemp-derived CBD brands, Lord Jones™ and PEACE+™.
Chairman, President & Chief Executive Officer
Mike Gorenstein is the Chairman, President and CEO of Cronos Group. Mike is also a Co-founder and Member of Gotham Green Partners. Before joining the Company, Mike was the VP and General Counsel at Alphabet Partners, LP, a New York City based multi-strategy investment management firm, focused on identifying mispriced assets across various industries, asset classes and geographies.
Prior to Alphabet Partners, LP, he was a corporate attorney at Sullivan & Cromwell LLP where he focused on mergers and acquisitions and capital markets transactions. Mike graduated from the University of Pennsylvania Law School with a Juris Doctor (JD), the Wharton School at University of Pennsylvania with a certificate in Business Economics and Public Policy and the Kelley School of Business at Indiana University with a Bachelor of Science Business in Finance.
The Globe and Mail
Mike GorensteinChairman, President & Chief Executive Officer Mike Gorenstein is the Chairman, President and CEO of Cronos Group. Mike is also a Co-founder and Member of Gotham Green Partners.
Before joining the Company, Mike was the VP and General Counsel at Alphabet Partners, LP, a New York City based multi-strategy investment management firm, focused on identifying mispriced assets across various industries, asset classes and geographies. Prior to Alphabet Partners, LP, he was a corporate attorney at Sullivan & Cromwell LLP where he focused on mergers and acquisitions and capital markets transactions.
Mike graduated from the University of Pennsylvania Law School with a Juris Doctor (JD), the Wharton School at University of Pennsylvania with a certificate in Business Economics and Public Policy and the Kelley School of Business at Indiana University with a Bachelor of Science Business in Finance. James RudykLead Director, Audit Committee Chair, Compensation Committee James Rudyk is currently the Chief Financial Officer of Roots Corporation ("Roots"), a position he has held since January 2016.
Mr. Rudyk is a seasoned executive with more than 25 years of financial and operational experience, and a track record of supporting ambitious growth plans. Prior to joining Roots, Mr. Rudyk served as the Chief Financial Officer of Shred-It International Inc. from 2009 to 2015, where he was instrumental in helping the company grow from approximately $200 million to over $700 million in revenue and expand to more than 17 countries around the world.
He also served as Chief Financial Officer and Chief Operating Officer of Canada Cartage Systems Limited from 2004 to 2009. He received his Bachelor of Arts and Master of Accounting degree from the University of Waterloo.
Mr. Rudyk is also a Chartered Professional Accountant and holds an ICD.D designation from the Institute of Corporate Directors. Jason AdlerIndependent Director, Compensation Committee Jason Adler is the Founder and Managing Partner of Gotham Green Partners GP ("Gotham Green"), the General Partner of Gotham Green Fund 1, LP, a private equity firm focused primarily on early-stage investing in companies in the cannabis industry.
Prior to founding Gotham Green, Mr.
Adler was the Co-founder and Chief Executive Officer of Alphabet Ventures, LLC, a New York based volatility fund, that focused on identifying mispriced assets across various industries, asset classes and geographies. Mr. Adler also founded Geronimo, LLC, a broker dealer and member of the American Stock Exchange, and he began his career as a Market Maker at G&D Trading.
Mr. Adler graduated with a Bachelor of Arts from the University of Rhode Island. Kevin Crosthwaite Kevin "K.C." Crosthwaite, Jr. serves as Senior Vice President and Chief Strategy and Growth Officer at Altria.
In this role, Mr. Crosthwaite identifies and pursues Altria’s strategic and innovative product growth priorities. Since joining Philip Morris USA in 1997, Mr. Crosthwaite has held several leadership positions across Altria’s family of companies, including President and Chief Executive Officer for Philip Morris USA, where he oversaw operations for Philip Morris USA and John Middleton, as well as Vice President, Strategy and Business Development, and Vice President & General Manager at Marlboro.
SITE TOUR: Cronos Group Inc (NASDAQ:CRON) Cannabis Production Backstage Pass
Crosthwaite also led Altria Ventures’ international efforts with innovative tobacco products. Mr. Crosthwaite currently serves on the Board of Directors for United Negro College Fund and the Richmond Forum. Mr. Crosthwaite received his Bachelor of Arts from Marquette University and his Master of Business Administration (MBA) from Providence College. Bronwen Evans Bronwen Evans is an independent consultant drawing on 20 years of experience in the charitable, corporate and government sectors to provide clients with business development and brand strategies for transformational growth.
Ms. Evans was a Founding Director of the True Patriot Love Foundation, where she served as its first CEO from 2012 to 2019 and raised record funds to support 25,000 Canadian military and veteran families. Before that, Ms. Evans was the Vice President of Marketing and Corporate Affairs at Medcan Health Management, and became the company’s first Chief Privacy Officer. She is a recipient of The Queen’s Diamond Jubilee Medal (2012) and currently serves as Director, Secretary and Chair of the Governance Committee of Kingsway College School.
Ms. Evans holds a Bachelor of Arts in Philosophy with Honors from McGill University, and a Master of Arts in Philosophy with a concentration in Biomedical Ethics from Carleton University. Murray Garnick Murray Garnick serves as Executive Vice President and General Counsel of Altria. In his role since 2017, he leads the company’s Law Department, Regulatory Affairs and Regulatory Sciences. Mr. Garnick previously served as Deputy General Counsel for Altria Client Services, a subsidiary of Altria, which provides professional services and support to Altria and its operating companies.
At Altria, Mr. Garnick has led the legal support for sales, marketing, regulation, and product development and intellectual property matters.
He has also supervised the management of tobacco, health and all other litigations brought against Altria and its operating companies.
Prior to joining Altria in 2008 as Senior Vice President, Litigation and Associate General Counsel, Mr. Garnick served for more than two decades as a senior litigation partner at the law firm of Arnold & Porter in Washington, D.C.
and currently serves on the Board of Trustees of Newseum in Washington, D.C. Mr. Garnick received his Bachelor of Arts from the University of Georgia and his Juris Doctor (JD) from the University of Georgia School of Law.
Bruce Gates Bruce Gates is a Founding Partner of Three Oaks Strategies LLC, a management, policy and communications consulting firm based in Alexandria, Virginia. He is also the founding partner of Three Oaks Asset Management LLC, a family office/venture capital firm. Prior to his retirement from Altria in November 2017, Mr. Gates served as a Senior Vice President of External Affairs for Altria Client Services. In his role, he led the Government Affairs and Corporate Affairs departments and directed the company’s strategies involving governments, corporate communications, philanthropic programs and corporate social responsibility.
Before assuming that role in 2011, Mr. Gates was Altria’s Senior Vice President of Government Affairs. He currently serves on the board of a private company, Aliro, and also on a number of non-profit boards, including The Boulder Crest Retreat for Wounded Warriors and Veteran Wellness, D.C.
Sail, and the Congressional Institute. Recently, he joined the Board of Trustees for the Ford’s Theatre. Mr. Gates received his Bachelor of Arts from the University of Georgia. David HsuChief Operating Officer David oversees all of Cronos Group’s operations including construction, cultivation and manufacturing as Chief Operating Officer. David is focused on continuous improvement by testing and integrating new technologies and automation to establish best practices in the cannabis industry.
Prior to joining Cronos Group, David spent over ten years consulting with Deloitte and CRG Partners, a premier turnaround consulting firm, where he operated and managed distressed companies with revenues more than $500M. His expertise includes financial and operational restructuring, growth creation, and lean manufacturing gleaned from experience working in various sectors including consumer packaged goods, manufacturing, distribution, media, and transportation.
David graduated from Babson College with a Bachelor of Science in Business Management and is a certified Lean Six Sigma Black Belt. William HilsonChief Commercial Officer William is responsible for further enhancing the commercial strategy of Cronos Group as well as the product and research development priorities of the company.
Prior to joining Cronos Group, William was the President of Hillhurst Management Inc. and CFO for EMD Inc. and Serono Canada Inc.
and Director of Finance for Hemosol Inc. William’s specialty is in pharmaceuticals with a proven track record of driving business objectives and growth, increasing efficiencies, overseeing clinical programs and product launch activities and increasing profit. William graduated from the University of Western Ontario with an Honors Bachelor of Science in Molecular Genetics, from the University of Toronto with a Master of Science Clinical Biochemistry.
His academic work has been published internationally. William was a member of the Board of Directors of EMD Inc., Canada and EMD Crop Bioscience and he is a member of Chartered Professional Accountants of Canada.
Jerry BarbatoChief Financial Officer Jerry is responsible for overseeing all aspects of Finance, Procurement and Human Resources. Jerry brings more than 20 years of experience in strategic planning, corporate financial analysis and services, and brand management. Prior to joining Cronos Group, Jerry held various roles within the Altria Group, Inc. family of companies. Jerry joined Altria in 2003 and served in leadership roles within the Finance, Strategy & Business Development and Marketing functions, and most recently held the role of Senior Director of Corporate Strategy.
He has broad experience in both finance and operating roles, as well as managing operations in regulated international markets. Jerry supported the Marlboro brand and provided analysis that shaped brand strategies for Altria’s smokeable segment. He also served as Assistant General Manager for a joint venture, Richmark GmbH, in Zurich, Switzerland.
Jerry holds a Bachelor of Science in Accounting from Marquette University and a Master of Business Administration (MBA) from the University of Maryland, University College. Xiuming ShumExecutive Vice President, Legal and Regulatory Affairs Xiuming manages all legal and regulatory affairs at Cronos Group, which informs the company’s strategy and execution. She also serves as the Company’s Corporate Secretary.
Xiuming has a decade of transactional and in-house experience in mergers and acquisitions and regulatory change management. Prior to joining Cronos Group, Xiuming served as in-house counsel at BNP Paribas’ Corporate and Institutional Banking division in New York and London, where she provided advice to senior management on disruptive and transformative legislative changes, such as the BASEL banking reforms, Brexit, and the Dodd-Frank Act.
Previously, she was a corporate attorney at Sullivan & Cromwell LLP in New York, where she focused on M&A in large, complex cross-border transactions in diverse industries, including alcohol and spirits, insurance, banking, private equity, and hedge funds.
Xiuming is a New York-qualified attorney, holding a Juris Doctor (JD) from Columbia Law School where she was a Harlan Fiske Stone Scholar and a first-class Bachelor of Laws degree from University College London in the U.K. Kevin GiffordVice President of Finance Kevin is a leading member of Cronos Group’s Corporate Finance team, he focuses on both internal and external reporting as well as advises the operations and financial functions within the company.
He has over 15 years of experiences in multiple industries, including consumer products, business services, retail and technology. Prior to joining Cronos Group, Kevin held a range of diverse investment roles at several private equity firms, as well as the Americas Special Situations Group at Goldman Sachs & Co., where he originated and executed transactions across the entire capital structure for middle-market companies. Additionally, Kevin worked in Deloitte’s Corporate Restructuring Group, where he improved performance of distressed companies in an interim C-level management or financial advisory capacity.
Kevin holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and a Master of Business Administration (MBA) from the University of Michigan. Eric KleinHead of Marketing Eric oversees Cronos Group’s marketing initiatives including brands, product innovation and consumer insights. Eric has spent a decade in brand management across several consumer-packaged goods companies.
Prior to joining Cronos Group, Eric oversaw strategy and innovation for the Water+ portfolio at PepsiCo working across several brands including Aquafina. He began his career at Mondelez working on Chips Ahoy!
and Oreo before joining Chobani, where he developed and grew the Flip business by 400 percent. Eric graduated with a Bachelor of Business Administration from Emory University with high honors and earned his Master of Business Administration (MBA) from University of Chicago Booth School of Business. Jeff JacobsonGeneral Manager, Canada and Europe As General Manager of Canada and Europe, Jeff is responsible for implementing and defining the strategy and execution across all areas of the Canadian and European business including sales, marketing and manufacturing operations.
Prior to joining Cronos Group, Jeff founded a Toronto based marketing agency and successfully launched and licensed several innovative software products in the mobile industry. As a co-founder of Peace Naturals, Jeff’s expertise and experience in licensing and compliance, new business development, project management and resource management help Cronos Group lead in domestic and international markets. Anna ShlimakHead of Investor Relations & Communications Anna is responsible for managing and directing the organization's internal and external communications, media relations as well as the company’s capital markets relationships and investor relations.
Your data, your experience
Prior to joining Cronos Group, Anna was the Head of Investor Relations at Quest Partners LLC, a research driven alternative investment firm. Anna was responsible for business development, investor reporting, marketing and communication initiatives for the company.
Previously, Anna held a range of diverse roles at the New York Stock Exchange in both the New York and London offices. Anna was on the Investor Relations Team within the Corporate Finance Group, where she was responsible for developing relationships with investors and sell side analysts and creating all investor communication and reporting. She holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and received a Master of Business Administration (MBA) from Columbia Business School.
Dr. Todd K. AbrahamChief Innovation Officer Dr. Todd K. Abraham is Cronos Group’s Chief Innovation Officer. Prior to joining the Company, Dr. Abraham was Senior Vice President of Research and Nutrition for Mondelēz International (formally Kraft Foods), and was responsible for worldwide technology development and strategy, scientific screening, nutritional science and communication, consumer guidance testing, analytical programs, R&D training and intellectual property strategy for a $35 billion multi-national business.
Prior to Mondelēz, Dr. Abraham served in various R&D, technology, marketing and product development roles for The Pillsbury Company and Procter & Gamble. Dr. Abraham received his Bachelor of Science degree in Chemistry at Brown University and his Doctor of Philosophy (Ph.D.) in Chemistry from the University of Pennsylvania and his Master of Business Administration (MBA) in Strategic Planning from the Wharton School at University of Pennsylvania.
Robert RosenheckChief Executive Officer, Redwood Robert Rosenheck is the Chief Executive Officer of Redwood, a hemp-derived CBD brand and products platform. In his role, Robert oversees Cronos Group’s operations, marketing and brand strategy for the U.S.
hemp-derived CBD market. Robert is also co-founder of the Lord Jones™ brand, which was the first hemp-derived CBD brand to be sold at both Sephora and SoulCycle. Prior to launching Lord Jones™, Robert was a partner at CAPOBIANCO, a Los Angeles-based creative agency specializing in launching and growing innovative brands. His past clients include General Mills, Sony Music, Puma, Credit Suisse, Paramount Pictures and Random House Publishing Group.
Robert received his Bachelor of Arts (BA) in Communications from the University of Pennsylvania.
Chairman, President & Chief Executive Officer
Executive Vice President, Legal and Regulatory Affairs
Chief Executive Officer, Redwood
General Manager, Canada and Europe
Vice President of Finance
Our mission is to improve people’s lives by unlocking the full potential of cannabis.
Our vision is to transform industries through cannabinoid innovation.
As we strive to improve people’s lives and generate long-term value for our stakeholders, we are guided by these principles:
People & Community
We believe in fostering the most valuable global cannabis community comprised of passionate and daring people.
We believe in developing innovative and meaningful products that meet the needs and exceed the expectations of our consumers.
Integrity & Leadership
We take pride in leading the industry forward responsibly.
Large_Logo_1_Cronos_Group.pngToronto, CanadaCanada’s regulatory environment allows Cronos Group to operate and innovate within a legal federal framework.
Toronto and the Greater Toronto Area are home to Cronos Group’s corporate headquarters and client care center. As Canada’s financial and economic center, Toronto is home to Cronos Group’s core executive operations, strategic planning, finance and governance. Operating in a federally legal environment allows Cronos Group to learn, build and create a leading company with an expanding global network.
Main_Image_1_Cronos_Group.jpg1ginkgo_bioworksredwoodLarge_Logo_16_Redwood.pngLos Angeles, California Redwood is a hemp-derived CBD brand and products platform headquartered in Los Angeles, California. Redwood oversees Cronos Group’s operations, marketing and brand strategy for the U.S. hemp-derived CBD market. Redwood currently supports two hemp-derived CBD brands, Lord Jones™ and PEACE+™.16Redwood.jpg2cronospnLarge_Logo_2_Peace_Naturals.pngStayner, Canada Cronos Group’s center of excellence, Peace Naturals, is a license holder under the Canadian Cannabis Act and a hub for the company’s production and research and development.
The campus’ state-of-the-art indoor production facilities and greenhouse serve as a home for research in plant genetics, grow methodologies, extraction and product formulation.
Cronos Group: This Weed Stock Has Double-Digit Upside
Peace Naturals develops industry-leading best practices, which are utilized throughout Cronos Group’s global network of production facilities.
Peace Naturals production processes are Good Manufacturing Practices (GMP) certified.Main_Image_2_Peace_Naturals.jpg3redwoodcfhttps://www.peacenaturals.com/Large_Logo_1_Cronos_Group.pngCronos Fermentation
Winnipeg, Manitoba, Canada Cronos Fermentation is an 84,000 square foot GMP compliant fermentation and manufacturing facility in Winnipeg, Canada.
The state-of-the-art facility includes fully equipped laboratories covering microbiology, organic and analytical chemistry, quality control and method development. This facility is expected to provide Cronos Group with the ability to produce cultured cannabinoids at commercial scale with high-quality and high purity. 3_Cronos_Fermentation_opt.jpg4pnogbcLarge_Logo_3_OGBC.pngOkanagan Valley, CanadaOriginal BC is a license holder under the Canadian Cannabis Act and is located in British Columbia’s Okanagan Valley.
Known for producing some of Canada’s best cannabis, this facility leverages the reputation of the Okanagan Valley. OGBC is focused on small-batch and craft cannabis production, perfected by our team of experts. Research and development at OGBC focuses on genetic breeding and phenotype research.Main_Image_3_OGBC.jpg5cfcdlLarge_Logo_1_Cronos_Group.pngCronos Device
Labs Bet Shemesh, Israel Cronos Device Labs is Cronos Group’s global center of research and development for vaporizer and device technology.
The team has over 80 years of combined expertise in vaporizer development, and is comprised of product designers, mechanical, electrical and software engineers, and analytical and formulation scientists.
Cronos Device Labs is expected to enable Cronos Group to deliver expanded product offerings to customers that are specially tailored to cannabinoid use.5_Cronos_Device_Labs_opt.jpg6ogbccronos_israelLarge_Logo_4_Cronos_Israel.pngGan Shmuel, Israel Cronos Group established a joint venture with Kibbutz Gan Shmuel, a commercial kibbutz and food company. Gan Shmuel exports to 35 countries across Europe and Asia, through Gan Shmuel Foods Ltd., and has over 1,000 agriculturally skilled kibbutz members who live on-site.
Cronos Israel has obtained preliminary licenses to establish nursery, cultivation, manufacturing and distribution operations and is in the process of constructing a custom-built greenhouse and manufacturing facility for cannabis.Main_Image_4_Cronos_Israel.jpg7cdlcronos_australiaLarge_Logo_5_Cronos_Australia.pngMelbourne, Australia Based in Melbourne, Cronos Australia plans to enter the medicinal cannabis market in Australia with a range of cannabinoid products, including PEACE NATURALS™ products, with plans to expand to Australasia.
Cronos Group owns 31% of Cronos Australia, which trades on the Australian Securities Exchange under the ticker symbol CAU.
7CronosAustralia.jpg8cronos_israelcronos_growCoLarge_Logo_6_Cronos_GrowCo.pngKingsville, CanadaCronos Group established a joint venture with a group of investors led by Bert Mucci, owner and operator of Mucci Farms, one of the most sophisticated greenhouse growers in North America. The Kingsville region is home to the largest concentration of greenhouses in North America and is commonly referred to as the “Sun Parlour,” since the area boasts one of the warmest climates in Canada.
Cronos GrowCo is in the process of constructing a custom-built greenhouse designed to meet GAP and GMP requirements.Main_Image_6_Cronos_GrowCo.jpg9cronos_australianatuEraLarge_Logo_7_NatuEra.pngCundinamarca, ColombiaCronos Group established a joint venture with Agroidea (AGI) to create NatuEra, the cannabis industry’s first Contract Manufacturing Organization (CMO) in LATAM. As a CMO, NatuEra intends to allow the growing number of cannabis brands worldwide to outsource their development, cultivation, and/or manufacturing activities.
NatuEra is expected to be the hub and platform through which Cronos Group will access the Latin American market. NatuEra holds licenses to cultivate non-psychoactive cannabis plants and manufacture derivative products, including for export. The JV plans to develop its initial cultivation and manufacturing operations with a custom-built facility.Main_Image_7_NatuEra.jpg10cronos_growComed_menhttps://www.agroidea.com.coLarge_Logo_8_MedMen.pngCanadaCronos Group has established a joint venture with MedMen, one of the most recognized cannabis retail brands, to create MedMen Canada.
Crons group ipo info
This partnership holds the exclusive license to the MedMen™ brand in Canada.Main_Image_8_MedMen.jpg11natuErapohl_boskampLarge_Logo_9_PohlBoskamp.pngGermanyCronos Group has an exclusive 5-year supply agreement with Pohl-Boskamp to distribute PEACE NATURALS™ products to medical patients in Germany. Founded in 1835, Pohl is an international pharmaceutical manufacturer and supplier that has a distribution network of 10,550 German pharmacies.Main_Image_9_PohlBoskamp.jpg12med_mendelfarmahttps://www.pohl-boskamp.de/Large_Logo_10_Delfarma.pngPoland Cronos Group has an exclusive 5-year supply agreement with Delfarma to distribute PEACE NATURALS™ products to medical patients in Poland.
Founded in 2004, Delfarma is an international pharmaceutical wholesaler that distributes products to 5,000 pharmacies and 200 hospitals, with a distribution network that reaches approximately 40% of the Polish domestic market.Main_Image_10_Delfarma.jpg13pohl_boskampcanadian_distributionhttp://delfarma.pl/enLarge_Logo_11_CanadianDistribution.pngCanada Our Canadian distribution includes Canada-wide, direct-to-patient access through the PEACE NATURALS™ brand.
Cronos Group participates in the Canadian adult-use market through its COVE™ and Spinach™ brands.
The company currently distributes to British Columbia, Alberta, Saskatchewan, Ontario, Nova Scotia and Prince Edward Island.
Main_Image_11_CanadianDistribution.jpg14delfarmatechnionLarge_Logo_12_Technion.pngHaifa, Israel Together with The Technion Research and Development Foundation, Cronos Group will explore the use of cannabinoids in regulating skin health and skin disorders.
Cronos Group Issues Statement on Separately Announced IPO of Cronos Australia
The research will utilize Technion’s cannabis strain database of over 80 cultivars and Cronos Group’s strain-specific cannabis oils to isolate and investigate the effects of individual and combinations of cannabinoids, for treatment of acne, psoriasis, and skin repair.Main_Image_12_Technion.jpg15canadian_distributionginkgo_bioworkshttps://www.technion.ac.il/en/home-2/Large_Logo_13_GinkgoBioworks.pngCronos Group entered into a landmark partnership to produce cultured cannabinoids at scale with Ginkgo Bioworks.
Using biosynthesis as the means of production, Cronos Group and Ginkgo Bioworks will reduce the cost of pure cannabinoid production, create commercial scale and the ability to access rare cannabinoids, which are key to product differentiation. Cronos Group will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally.Main_Image_13_GinkgoBioworks.jpg16technioncronoshttps://www.ginkgobioworks.com/